158 related articles for article (PubMed ID: 10605717)
21. Urokinase (u-PA) is produced by collecting duct principal cells and is post-transcriptionally regulated by SV40 large-T, arginine vasopressin, and epidermal growth factor.
Piedagnel R; Tiger Y; Lelongt B; Ronco PM
J Cell Physiol; 2006 Feb; 206(2):394-401. PubMed ID: 16155905
[TBL] [Abstract][Full Text] [Related]
22. Plasminogen activator system in oral squamous cell carcinoma.
Baker EA; Leaper DJ; Hayter JP; Dickenson AJ
Br J Oral Maxillofac Surg; 2007 Dec; 45(8):623-7. PubMed ID: 17590247
[TBL] [Abstract][Full Text] [Related]
23. Growth factor-dependent proliferation and invasion of muscle satellite cells require the cell-associated fibrinolytic system.
Fibbi G; D'Alessio S; Pucci M; Cerletti M; Del Rosso M
Biol Chem; 2002 Jan; 383(1):127-36. PubMed ID: 11928807
[TBL] [Abstract][Full Text] [Related]
24. Urokinase-type plasminogen activator system and breast cancer (Review).
Han B; Nakamura M; Mori I; Nakamura Y; Kakudo K
Oncol Rep; 2005 Jul; 14(1):105-12. PubMed ID: 15944776
[TBL] [Abstract][Full Text] [Related]
25. Wound-induced migration of MDA-MB-435 and SKOV-3 cancer cells is regulated by plasminogen activator inhibitor-1.
Whitley BR; Church FC
Int J Oncol; 2005 Sep; 27(3):749-57. PubMed ID: 16077925
[TBL] [Abstract][Full Text] [Related]
26. Urokinase-type plasminogen activator-induced monocyte adhesion is modulated by kininogen, kallikrein, factor XII, and plasminogen.
Li C; Gurewich V; Liu JN
Exp Cell Res; 1996 Aug; 226(2):239-42. PubMed ID: 8806427
[TBL] [Abstract][Full Text] [Related]
27. uPA and uPAR in fibrinolysis, immunity and pathology.
Mondino A; Blasi F
Trends Immunol; 2004 Aug; 25(8):450-5. PubMed ID: 15275645
[No Abstract] [Full Text] [Related]
28. Urokinase-type plasminogen activator, receptor, and inhibitor correlating with gelatinase-B (MMP-9) contribute to inflammation in gouty arthritis of the knee.
Chu SC; Yang SF; Lue KH; Hsieh YS; Hsiao TY; Lu KH
J Rheumatol; 2006 Feb; 33(2):311-7. PubMed ID: 16465663
[TBL] [Abstract][Full Text] [Related]
29. Identification of markers of possible prognostic value in 57 giant cell tumors of bone.
Gamberi G; Serra M; Ragazzini P; Magagnoli G; Pazzaglia L; Ponticelli F; Ferrari C; Zanasi M; Bertoni F; Picci P; Benassi MS
Oncol Rep; 2003; 10(2):351-6. PubMed ID: 12579271
[TBL] [Abstract][Full Text] [Related]
30. Expression of urokinase, plasminogen activator inhibitors and urokinase receptor in pregnant rhesus monkey uterus during early placentation.
Feng Q; Liu Y; Liu K; Byrne S; Liu G; Wang X; Li Z; Ockleford CD
Placenta; 2000; 21(2-3):184-93. PubMed ID: 10736241
[TBL] [Abstract][Full Text] [Related]
31. The urokinase plasminogen activator system: a rich source of tumour markers for the individualised management of patients with cancer.
Duffy MJ; Duggan C
Clin Biochem; 2004 Jul; 37(7):541-8. PubMed ID: 15234235
[TBL] [Abstract][Full Text] [Related]
32. Expression of active plasminogen activator inhibitor-1 reduces cell migration and invasion in breast and gynecological cancer cells.
Whitley BR; Palmieri D; Twerdi CD; Church FC
Exp Cell Res; 2004 Jun; 296(2):151-62. PubMed ID: 15149846
[TBL] [Abstract][Full Text] [Related]
33. Modulation of invasive properties of human glioblastoma cells stably expressing amino-terminal fragment of urokinase-type plasminogen activator.
Mohanam S; Chandrasekar N; Yanamandra N; Khawar S; Mirza F; Dinh DH; Olivero WC; Rao JS
Oncogene; 2002 Nov; 21(51):7824-30. PubMed ID: 12420219
[TBL] [Abstract][Full Text] [Related]
34. Extracellular matrix metalloproteinase inducer up-regulates the urokinase-type plasminogen activator system promoting tumor cell invasion.
Quemener C; Gabison EE; Naïmi B; Lescaille G; Bougatef F; Podgorniak MP; Labarchède G; Lebbé C; Calvo F; Menashi S; Mourah S
Cancer Res; 2007 Jan; 67(1):9-15. PubMed ID: 17210677
[TBL] [Abstract][Full Text] [Related]
35. Interleukin-1alpha enhances the aggressive behavior of pancreatic cancer cells by regulating the alpha6beta1-integrin and urokinase plasminogen activator receptor expression.
Sawai H; Okada Y; Funahashi H; Matsuo Y; Takahashi H; Takeyama H; Manabe T
BMC Cell Biol; 2006 Feb; 7():8. PubMed ID: 16504015
[TBL] [Abstract][Full Text] [Related]
36. Post-transcriptional regulation of gene expression in the plasminogen activation system.
Montuori N; Rossi G; Ragno P
Biol Chem; 2002 Jan; 383(1):47-53. PubMed ID: 11928821
[TBL] [Abstract][Full Text] [Related]
37. Cell motility. Making connections count.
Lauffenburger DA
Nature; 1996 Oct; 383(6599):390-1. PubMed ID: 8837766
[No Abstract] [Full Text] [Related]
38. Urokinase plasminogen activator (uPA) and its type 1 inhibitor (PAI-1): regulators of proteolysis during cancer invasion and prognostic parameters in breast cancer.
Brünner N; Pyke C; Hansen CH; Rømer J; Grøndahl-Hansen J; Danø K
Cancer Treat Res; 1994; 71():299-309. PubMed ID: 7946954
[No Abstract] [Full Text] [Related]
39. Src-dependence and pertussis-toxin sensitivity of urokinase receptor-dependent chemotaxis and cytoskeleton reorganization in rat smooth muscle cells.
Degryse B; Resnati M; Rabbani SA; Villa A; Fazioli F; Blasi F
Blood; 1999 Jul; 94(2):649-62. PubMed ID: 10397732
[TBL] [Abstract][Full Text] [Related]
40. Regulation of cell adhesion by PAI-1.
Loskutoff DJ; Curriden SA; Hu G; Deng G
APMIS; 1999 Jan; 107(1):54-61. PubMed ID: 10190280
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
